Viking Therapeutics Inc
NASDAQ:VKTX

Watchlist Manager
Viking Therapeutics Inc Logo
Viking Therapeutics Inc
NASDAQ:VKTX
Watchlist
Price: 30.745 USD 1.1%
Market Cap: $3.5B

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Viking Therapeutics Inc
NASDAQ:VKTX
3.4B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Viking Therapeutics Inc
Glance View

Viking Therapeutics Inc. stands at the intriguing intersection of clinical innovation and strategic execution, carving a unique niche in the biotechnology landscape. Founded with a mission to develop novel, first-in-class or best-in-class therapies, Viking Therapeutics is primarily focused on the areas of metabolic and endocrine disorders. Through harnessing cutting-edge science, the company is developing a robust portfolio of drug candidates aimed at tackling some of the most challenging and widespread health conditions. Its flagship product candidates include VK2809 and VK0214, both of which are addressing significant unmet needs in the treatment of nonalcoholic steatohepatitis (NASH), hypercholesterolemia, and X-linked adrenoleukodystrophy (X-ALD), respectively. Viking Therapeutics operates by capitalizing on its expertise in gene transcription regulation, specifically targeting metabolic pathways to alter disease progression. The company's business model leans heavily on progression through clinical trial phases, with the ultimate goal of securing Food and Drug Administration (FDA) approvals that can later translate into profitable licensing agreements or partnerships with larger pharmaceutical companies. By advancing these therapies through the meticulous phases of drug development, Viking aims to monetize its investments in research and development by leveraging the lucrative nature of market approvals and commercial partnerships. Through this meticulous balancing act of innovation and strategic alliances, Viking Therapeutics encapsulates the dynamic and high-stakes world of biotech entrepreneurship.

VKTX Intrinsic Value
0.012 USD
Overvaluation 100%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top